SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Aclara developed microfluidic lab-on-a-chip technology with applications for genomics, high-throughput drug screening and clinical diagnostics. The company’s technology substantially enlarged throughput capacity while dramatically lowering costs compared with competing approaches. The cornerstone of Aclara’s product development strategy was a disposable plastic or glass “chip” called a LabCard that enabled the computerized control of the movement, measurement and mixing of liquids without the use of moving parts or valves.
Aclara Biosciences
Mountain View, CA
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.